Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Identifieur interne : 003B44 ( Ncbi/Merge ); précédent : 003B43; suivant : 003B45Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Auteurs : P. Marcellin [France] ; S H Ahn [Corée du Sud] ; W-L Chuang [Taïwan] ; A J Hui [République populaire de Chine] ; F. Tabak [Turquie] ; R. Mehta [Inde] ; J. Petersen [Allemagne] ; C-M Lee [Taïwan] ; X. Ma [États-Unis] ; F A Caruntu [Roumanie] ; W Y Tak [Corée du Sud] ; M. Elkhashab [Canada] ; L. Lin [États-Unis] ; G. Wu [États-Unis] ; E B Martins [États-Unis] ; P. Charuworn [États-Unis] ; L J Yee [États-Unis] ; S G Lim ; G R Foster [Royaume-Uni] ; S. Fung [Canada] ; L. Morano [Espagne] ; D. Samuel [France] ; K. Agarwal [Royaume-Uni] ; R. Idilman [Turquie] ; S I Strasser [Australie] ; M. Buti [Espagne] ; G B Gaeta [Italie] ; G. Papatheodoridis [Grèce] ; R. Flisiak [Pologne] ; H L Y. Chan [République populaire de Chine]Source :
- Alimentary pharmacology & therapeutics [ 1365-2036 ] ; 2016.
Descripteurs français
- KwdFr :
- ADN viral (sang), Administration par voie orale, Adulte, Adulte d'âge moyen, Antigènes de surface du virus de l'hépatite B (sang), Antiviraux (administration et posologie), Association de médicaments, Femelle, Humains, Hépatite B chronique (diagnostic), Hépatite B chronique (traitement médicamenteux), Injections sous-cutanées, Interféron alpha (administration et posologie), Mâle, Polyéthylène glycols (administration et posologie), Protéines recombinantes (administration et posologie), Résultat thérapeutique, Ténofovir (administration et posologie), Valeur prédictive des tests, Virus de l'hépatite B (), Virus de l'hépatite B (génétique).
- MESH :
- administration et posologie : Antiviraux, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ténofovir.
- diagnostic : Hépatite B chronique.
- génétique : Virus de l'hépatite B.
- sang : ADN viral, Antigènes de surface du virus de l'hépatite B.
- traitement médicamenteux : Hépatite B chronique.
- Administration par voie orale, Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Humains, Injections sous-cutanées, Mâle, Résultat thérapeutique, Valeur prédictive des tests, Virus de l'hépatite B.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Antiviral Agents (administration & dosage), DNA, Viral (blood), Drug Therapy, Combination, Female, Hepatitis B Surface Antigens (blood), Hepatitis B virus (drug effects), Hepatitis B virus (genetics), Hepatitis B, Chronic (diagnosis), Hepatitis B, Chronic (drug therapy), Humans, Injections, Subcutaneous, Interferon-alpha (administration & dosage), Male, Middle Aged, Polyethylene Glycols (administration & dosage), Predictive Value of Tests, Recombinant Proteins (administration & dosage), Tenofovir (administration & dosage), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Tenofovir.
- chemical , blood : DNA, Viral, Hepatitis B Surface Antigens.
- diagnosis : Hepatitis B, Chronic.
- drug effects : Hepatitis B virus.
- drug therapy : Hepatitis B, Chronic.
- genetics : Hepatitis B virus.
- Administration, Oral, Adult, Drug Therapy, Combination, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Predictive Value of Tests, Treatment Outcome.
Abstract
In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
DOI: 10.1111/apt.13779
PubMed: 27629859
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001689
- to stream PubMed, to step Curation: 001667
- to stream PubMed, to step Checkpoint: 001667
Links to Exploration step
pubmed:27629859Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.</title><author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name><affiliation wicri:level="1"><nlm:affiliation>Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Paris</wicri:regionArea></affiliation></author><author><name sortKey="Ahn, S H" sort="Ahn, S H" uniqKey="Ahn S" first="S H" last="Ahn">S H Ahn</name><affiliation wicri:level="1"><nlm:affiliation>Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Seoul</wicri:regionArea></affiliation></author><author><name sortKey="Chuang, W L" sort="Chuang, W L" uniqKey="Chuang W" first="W-L" last="Chuang">W-L Chuang</name><affiliation wicri:level="1"><nlm:affiliation>Kaohsiung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Kaohsiung</wicri:regionArea></affiliation></author><author><name sortKey="Hui, A J" sort="Hui, A J" uniqKey="Hui A" first="A J" last="Hui">A J Hui</name><affiliation wicri:level="1"><nlm:affiliation>Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Tabak, F" sort="Tabak, F" uniqKey="Tabak F" first="F" last="Tabak">F. Tabak</name><affiliation wicri:level="1"><nlm:affiliation>Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Mehta, R" sort="Mehta, R" uniqKey="Mehta R" first="R" last="Mehta">R. Mehta</name><affiliation wicri:level="1"><nlm:affiliation>Surat, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Surat</wicri:regionArea></affiliation></author><author><name sortKey="Petersen, J" sort="Petersen, J" uniqKey="Petersen J" first="J" last="Petersen">J. Petersen</name><affiliation wicri:level="1"><nlm:affiliation>Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Lee, C M" sort="Lee, C M" uniqKey="Lee C" first="C-M" last="Lee">C-M Lee</name><affiliation wicri:level="1"><nlm:affiliation>Kaohsiung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Kaohsiung</wicri:regionArea></affiliation></author><author><name sortKey="Ma, X" sort="Ma, X" uniqKey="Ma X" first="X" last="Ma">X. Ma</name><affiliation wicri:level="1"><nlm:affiliation>Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Philadelphia</wicri:regionArea></affiliation></author><author><name sortKey="Caruntu, F A" sort="Caruntu, F A" uniqKey="Caruntu F" first="F A" last="Caruntu">F A Caruntu</name><affiliation wicri:level="1"><nlm:affiliation>Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Bucharest</wicri:regionArea></affiliation></author><author><name sortKey="Tak, W Y" sort="Tak, W Y" uniqKey="Tak W" first="W Y" last="Tak">W Y Tak</name><affiliation wicri:level="1"><nlm:affiliation>Daegu, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Daegu</wicri:regionArea></affiliation></author><author><name sortKey="Elkhashab, M" sort="Elkhashab, M" uniqKey="Elkhashab M" first="M" last="Elkhashab">M. Elkhashab</name><affiliation wicri:level="1"><nlm:affiliation>Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Lin, L" sort="Lin, L" uniqKey="Lin L" first="L" last="Lin">L. Lin</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wu, G" sort="Wu, G" uniqKey="Wu G" first="G" last="Wu">G. Wu</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Martins, E B" sort="Martins, E B" uniqKey="Martins E" first="E B" last="Martins">E B Martins</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Charuworn, P" sort="Charuworn, P" uniqKey="Charuworn P" first="P" last="Charuworn">P. Charuworn</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yee, L J" sort="Yee, L J" uniqKey="Yee L" first="L J" last="Yee">L J Yee</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lim, S G" sort="Lim, S G" uniqKey="Lim S" first="S G" last="Lim">S G Lim</name><affiliation><nlm:affiliation>Singapore.</nlm:affiliation><wicri:noCountry code="no comma">Singapore.</wicri:noCountry></affiliation></author><author><name sortKey="Foster, G R" sort="Foster, G R" uniqKey="Foster G" first="G R" last="Foster">G R Foster</name><affiliation wicri:level="1"><nlm:affiliation>London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London</wicri:regionArea></affiliation></author><author><name sortKey="Fung, S" sort="Fung, S" uniqKey="Fung S" first="S" last="Fung">S. Fung</name><affiliation wicri:level="1"><nlm:affiliation>Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Morano, L" sort="Morano, L" uniqKey="Morano L" first="L" last="Morano">L. Morano</name><affiliation wicri:level="1"><nlm:affiliation>Pontevedra, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pontevedra</wicri:regionArea></affiliation></author><author><name sortKey="Samuel, D" sort="Samuel, D" uniqKey="Samuel D" first="D" last="Samuel">D. Samuel</name><affiliation wicri:level="1"><nlm:affiliation>Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Agarwal, K" sort="Agarwal, K" uniqKey="Agarwal K" first="K" last="Agarwal">K. Agarwal</name><affiliation wicri:level="1"><nlm:affiliation>London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London</wicri:regionArea></affiliation></author><author><name sortKey="Idilman, R" sort="Idilman, R" uniqKey="Idilman R" first="R" last="Idilman">R. Idilman</name><affiliation wicri:level="1"><nlm:affiliation>Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Ankara</wicri:regionArea></affiliation></author><author><name sortKey="Strasser, S I" sort="Strasser, S I" uniqKey="Strasser S" first="S I" last="Strasser">S I Strasser</name><affiliation wicri:level="1"><nlm:affiliation>Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name><affiliation wicri:level="1"><nlm:affiliation>Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Gaeta, G B" sort="Gaeta, G B" uniqKey="Gaeta G" first="G B" last="Gaeta">G B Gaeta</name><affiliation wicri:level="1"><nlm:affiliation>Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Naples</wicri:regionArea></affiliation></author><author><name sortKey="Papatheodoridis, G" sort="Papatheodoridis, G" uniqKey="Papatheodoridis G" first="G" last="Papatheodoridis">G. Papatheodoridis</name><affiliation wicri:level="1"><nlm:affiliation>Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Athens</wicri:regionArea></affiliation></author><author><name sortKey="Flisiak, R" sort="Flisiak, R" uniqKey="Flisiak R" first="R" last="Flisiak">R. Flisiak</name><affiliation wicri:level="1"><nlm:affiliation>Bialystok, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Bialystok</wicri:regionArea></affiliation></author><author><name sortKey="Chan, H L Y" sort="Chan, H L Y" uniqKey="Chan H" first="H L Y" last="Chan">H L Y. Chan</name><affiliation wicri:level="1"><nlm:affiliation>Hong Kong, China. hlychan@cuhk.edu.hk.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27629859</idno><idno type="pmid">27629859</idno><idno type="doi">10.1111/apt.13779</idno><idno type="wicri:Area/PubMed/Corpus">001689</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001689</idno><idno type="wicri:Area/PubMed/Curation">001667</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001667</idno><idno type="wicri:Area/PubMed/Checkpoint">001667</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001667</idno><idno type="wicri:Area/Ncbi/Merge">003B44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.</title><author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name><affiliation wicri:level="1"><nlm:affiliation>Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Paris</wicri:regionArea></affiliation></author><author><name sortKey="Ahn, S H" sort="Ahn, S H" uniqKey="Ahn S" first="S H" last="Ahn">S H Ahn</name><affiliation wicri:level="1"><nlm:affiliation>Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Seoul</wicri:regionArea></affiliation></author><author><name sortKey="Chuang, W L" sort="Chuang, W L" uniqKey="Chuang W" first="W-L" last="Chuang">W-L Chuang</name><affiliation wicri:level="1"><nlm:affiliation>Kaohsiung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Kaohsiung</wicri:regionArea></affiliation></author><author><name sortKey="Hui, A J" sort="Hui, A J" uniqKey="Hui A" first="A J" last="Hui">A J Hui</name><affiliation wicri:level="1"><nlm:affiliation>Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Tabak, F" sort="Tabak, F" uniqKey="Tabak F" first="F" last="Tabak">F. Tabak</name><affiliation wicri:level="1"><nlm:affiliation>Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Mehta, R" sort="Mehta, R" uniqKey="Mehta R" first="R" last="Mehta">R. Mehta</name><affiliation wicri:level="1"><nlm:affiliation>Surat, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Surat</wicri:regionArea></affiliation></author><author><name sortKey="Petersen, J" sort="Petersen, J" uniqKey="Petersen J" first="J" last="Petersen">J. Petersen</name><affiliation wicri:level="1"><nlm:affiliation>Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Lee, C M" sort="Lee, C M" uniqKey="Lee C" first="C-M" last="Lee">C-M Lee</name><affiliation wicri:level="1"><nlm:affiliation>Kaohsiung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Kaohsiung</wicri:regionArea></affiliation></author><author><name sortKey="Ma, X" sort="Ma, X" uniqKey="Ma X" first="X" last="Ma">X. Ma</name><affiliation wicri:level="1"><nlm:affiliation>Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Philadelphia</wicri:regionArea></affiliation></author><author><name sortKey="Caruntu, F A" sort="Caruntu, F A" uniqKey="Caruntu F" first="F A" last="Caruntu">F A Caruntu</name><affiliation wicri:level="1"><nlm:affiliation>Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Bucharest</wicri:regionArea></affiliation></author><author><name sortKey="Tak, W Y" sort="Tak, W Y" uniqKey="Tak W" first="W Y" last="Tak">W Y Tak</name><affiliation wicri:level="1"><nlm:affiliation>Daegu, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Daegu</wicri:regionArea></affiliation></author><author><name sortKey="Elkhashab, M" sort="Elkhashab, M" uniqKey="Elkhashab M" first="M" last="Elkhashab">M. Elkhashab</name><affiliation wicri:level="1"><nlm:affiliation>Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Lin, L" sort="Lin, L" uniqKey="Lin L" first="L" last="Lin">L. Lin</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wu, G" sort="Wu, G" uniqKey="Wu G" first="G" last="Wu">G. Wu</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Martins, E B" sort="Martins, E B" uniqKey="Martins E" first="E B" last="Martins">E B Martins</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Charuworn, P" sort="Charuworn, P" uniqKey="Charuworn P" first="P" last="Charuworn">P. Charuworn</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yee, L J" sort="Yee, L J" uniqKey="Yee L" first="L J" last="Yee">L J Yee</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Inc., Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lim, S G" sort="Lim, S G" uniqKey="Lim S" first="S G" last="Lim">S G Lim</name><affiliation><nlm:affiliation>Singapore.</nlm:affiliation><wicri:noCountry code="no comma">Singapore.</wicri:noCountry></affiliation></author><author><name sortKey="Foster, G R" sort="Foster, G R" uniqKey="Foster G" first="G R" last="Foster">G R Foster</name><affiliation wicri:level="1"><nlm:affiliation>London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London</wicri:regionArea></affiliation></author><author><name sortKey="Fung, S" sort="Fung, S" uniqKey="Fung S" first="S" last="Fung">S. Fung</name><affiliation wicri:level="1"><nlm:affiliation>Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Morano, L" sort="Morano, L" uniqKey="Morano L" first="L" last="Morano">L. Morano</name><affiliation wicri:level="1"><nlm:affiliation>Pontevedra, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pontevedra</wicri:regionArea></affiliation></author><author><name sortKey="Samuel, D" sort="Samuel, D" uniqKey="Samuel D" first="D" last="Samuel">D. Samuel</name><affiliation wicri:level="1"><nlm:affiliation>Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Agarwal, K" sort="Agarwal, K" uniqKey="Agarwal K" first="K" last="Agarwal">K. Agarwal</name><affiliation wicri:level="1"><nlm:affiliation>London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London</wicri:regionArea></affiliation></author><author><name sortKey="Idilman, R" sort="Idilman, R" uniqKey="Idilman R" first="R" last="Idilman">R. Idilman</name><affiliation wicri:level="1"><nlm:affiliation>Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Ankara</wicri:regionArea></affiliation></author><author><name sortKey="Strasser, S I" sort="Strasser, S I" uniqKey="Strasser S" first="S I" last="Strasser">S I Strasser</name><affiliation wicri:level="1"><nlm:affiliation>Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name><affiliation wicri:level="1"><nlm:affiliation>Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Gaeta, G B" sort="Gaeta, G B" uniqKey="Gaeta G" first="G B" last="Gaeta">G B Gaeta</name><affiliation wicri:level="1"><nlm:affiliation>Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Naples</wicri:regionArea></affiliation></author><author><name sortKey="Papatheodoridis, G" sort="Papatheodoridis, G" uniqKey="Papatheodoridis G" first="G" last="Papatheodoridis">G. Papatheodoridis</name><affiliation wicri:level="1"><nlm:affiliation>Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Athens</wicri:regionArea></affiliation></author><author><name sortKey="Flisiak, R" sort="Flisiak, R" uniqKey="Flisiak R" first="R" last="Flisiak">R. Flisiak</name><affiliation wicri:level="1"><nlm:affiliation>Bialystok, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Bialystok</wicri:regionArea></affiliation></author><author><name sortKey="Chan, H L Y" sort="Chan, H L Y" uniqKey="Chan H" first="H L Y" last="Chan">H L Y. Chan</name><affiliation wicri:level="1"><nlm:affiliation>Hong Kong, China. hlychan@cuhk.edu.hk.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong</wicri:regionArea></affiliation></author></analytic><series><title level="j">Alimentary pharmacology & therapeutics</title><idno type="eISSN">1365-2036</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Antiviral Agents (administration & dosage)</term><term>DNA, Viral (blood)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Hepatitis B Surface Antigens (blood)</term><term>Hepatitis B virus (drug effects)</term><term>Hepatitis B virus (genetics)</term><term>Hepatitis B, Chronic (diagnosis)</term><term>Hepatitis B, Chronic (drug therapy)</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Interferon-alpha (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Polyethylene Glycols (administration & dosage)</term><term>Predictive Value of Tests</term><term>Recombinant Proteins (administration & dosage)</term><term>Tenofovir (administration & dosage)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (sang)</term><term>Administration par voie orale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antigènes de surface du virus de l'hépatite B (sang)</term><term>Antiviraux (administration et posologie)</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Hépatite B chronique (diagnostic)</term><term>Hépatite B chronique (traitement médicamenteux)</term><term>Injections sous-cutanées</term><term>Interféron alpha (administration et posologie)</term><term>Mâle</term><term>Polyéthylène glycols (administration et posologie)</term><term>Protéines recombinantes (administration et posologie)</term><term>Résultat thérapeutique</term><term>Ténofovir (administration et posologie)</term><term>Valeur prédictive des tests</term><term>Virus de l'hépatite B ()</term><term>Virus de l'hépatite B (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>DNA, Viral</term><term>Hepatitis B Surface Antigens</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>ADN viral</term><term>Antigènes de surface du virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Valeur prédictive des tests</term><term>Virus de l'hépatite B</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27629859</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>15</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alimentary pharmacology & therapeutics</Title><ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation></Journal><ArticleTitle>Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.</ArticleTitle><Pagination><MedlinePgn>957-966</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.13779</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To identify baseline and on-treatment factors associated with HBsAg loss at Week 72 and provide a model for predicting HBsAg loss in patients receiving combination therapy for 48 weeks.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A secondary analysis of data from an open-label study where patients were randomised to TDF (300 mg/day, oral) plus PEG-IFN (PI, 180 μg/week, subcutaneous) for 48 weeks (TDF/PI-48w); TDF plus PEG-IFN for 16 weeks, TDF for 32 weeks (TDF/PI-16w+TDF-32w); TDF for 120 weeks (TDF-120w) or PEG-IFN for 48 weeks (PI-48w). Logistic regression methods were used to identify models that best predicted HBsAg loss at Week 72.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09). The only baseline factor associated with response was genotype A. HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001). HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.</AbstractText><CopyrightInformation>© 2016 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marcellin</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>S H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>W-L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabak</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Surat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C-M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruntu</LastName><ForeName>F A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tak</LastName><ForeName>W Y</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkhashab</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>E B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charuworn</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>L J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>S G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>G R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fung</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morano</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pontevedra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samuel</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idilman</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strasser</LastName><ForeName>S I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buti</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaeta</LastName><ForeName>G B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papatheodoridis</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flisiak</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>H L Y</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Hong Kong, China. hlychan@cuhk.edu.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q46947FE7K</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27629859</ArticleId><ArticleId IdType="doi">10.1111/apt.13779</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Corée du Sud</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Inde</li><li>Italie</li><li>Pologne</li><li>Roumanie</li><li>Royaume-Uni</li><li>République populaire de Chine</li><li>Taïwan</li><li>Turquie</li><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Lim, S G" sort="Lim, S G" uniqKey="Lim S" first="S G" last="Lim">S G Lim</name></noCountry><country name="France"><noRegion><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name></noRegion><name sortKey="Samuel, D" sort="Samuel, D" uniqKey="Samuel D" first="D" last="Samuel">D. Samuel</name></country><country name="Corée du Sud"><noRegion><name sortKey="Ahn, S H" sort="Ahn, S H" uniqKey="Ahn S" first="S H" last="Ahn">S H Ahn</name></noRegion><name sortKey="Tak, W Y" sort="Tak, W Y" uniqKey="Tak W" first="W Y" last="Tak">W Y Tak</name></country><country name="Taïwan"><noRegion><name sortKey="Chuang, W L" sort="Chuang, W L" uniqKey="Chuang W" first="W-L" last="Chuang">W-L Chuang</name></noRegion><name sortKey="Lee, C M" sort="Lee, C M" uniqKey="Lee C" first="C-M" last="Lee">C-M Lee</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Hui, A J" sort="Hui, A J" uniqKey="Hui A" first="A J" last="Hui">A J Hui</name></noRegion><name sortKey="Chan, H L Y" sort="Chan, H L Y" uniqKey="Chan H" first="H L Y" last="Chan">H L Y. Chan</name></country><country name="Turquie"><noRegion><name sortKey="Tabak, F" sort="Tabak, F" uniqKey="Tabak F" first="F" last="Tabak">F. Tabak</name></noRegion><name sortKey="Idilman, R" sort="Idilman, R" uniqKey="Idilman R" first="R" last="Idilman">R. Idilman</name></country><country name="Inde"><noRegion><name sortKey="Mehta, R" sort="Mehta, R" uniqKey="Mehta R" first="R" last="Mehta">R. Mehta</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Petersen, J" sort="Petersen, J" uniqKey="Petersen J" first="J" last="Petersen">J. Petersen</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Ma, X" sort="Ma, X" uniqKey="Ma X" first="X" last="Ma">X. Ma</name></noRegion><name sortKey="Charuworn, P" sort="Charuworn, P" uniqKey="Charuworn P" first="P" last="Charuworn">P. Charuworn</name><name sortKey="Lin, L" sort="Lin, L" uniqKey="Lin L" first="L" last="Lin">L. Lin</name><name sortKey="Martins, E B" sort="Martins, E B" uniqKey="Martins E" first="E B" last="Martins">E B Martins</name><name sortKey="Wu, G" sort="Wu, G" uniqKey="Wu G" first="G" last="Wu">G. Wu</name><name sortKey="Yee, L J" sort="Yee, L J" uniqKey="Yee L" first="L J" last="Yee">L J Yee</name></country><country name="Roumanie"><noRegion><name sortKey="Caruntu, F A" sort="Caruntu, F A" uniqKey="Caruntu F" first="F A" last="Caruntu">F A Caruntu</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Elkhashab, M" sort="Elkhashab, M" uniqKey="Elkhashab M" first="M" last="Elkhashab">M. Elkhashab</name></noRegion><name sortKey="Fung, S" sort="Fung, S" uniqKey="Fung S" first="S" last="Fung">S. Fung</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Foster, G R" sort="Foster, G R" uniqKey="Foster G" first="G R" last="Foster">G R Foster</name></noRegion><name sortKey="Agarwal, K" sort="Agarwal, K" uniqKey="Agarwal K" first="K" last="Agarwal">K. Agarwal</name></country><country name="Espagne"><noRegion><name sortKey="Morano, L" sort="Morano, L" uniqKey="Morano L" first="L" last="Morano">L. Morano</name></noRegion><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name></country><country name="Australie"><noRegion><name sortKey="Strasser, S I" sort="Strasser, S I" uniqKey="Strasser S" first="S I" last="Strasser">S I Strasser</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Gaeta, G B" sort="Gaeta, G B" uniqKey="Gaeta G" first="G B" last="Gaeta">G B Gaeta</name></noRegion></country><country name="Grèce"><noRegion><name sortKey="Papatheodoridis, G" sort="Papatheodoridis, G" uniqKey="Papatheodoridis G" first="G" last="Papatheodoridis">G. Papatheodoridis</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Flisiak, R" sort="Flisiak, R" uniqKey="Flisiak R" first="R" last="Flisiak">R. Flisiak</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003B44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27629859
|texte= Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27629859" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |